Serum TATI levels and clinical correlation in tumors of the head and neck.
By radioimmunoassay (RIA) we studied tumor-associated trypsin inhibitor (TATI) in 152 serum samples, divided into three groups: 35 healthy subjects, used as controls; 25 individuals with benign pathology of the ear, nose and throat (ENT) region; 92 serial samples obtained from 69 patients with malignant disease of the head and neck. The malignant ENT group were classified in four stages according to the degree of tumor activity. The TATI concentrations (mean +/- SD) were as follows: control group, 16.0 +/- 3.4; benign group, 17.1 +/- 6.7; A0, 14.8 +/- 11.5; A1, 12.1 +/- 3.5; A2, 17.01 +/- 1.4; A3, 43.0 +/- 54.9.
Rayo
J I
JI
Nuclear Medicine Service, University Hospital of Salamanca, Spain.
Garcia-Talavera
J R
JR
Martin
M
M
Muñoz
A
A
Del Cañizo
A
A
D014408:Biomarkers, Tumor / Q000097:blood*; D006258:Head and Neck Neoplasms / Q000097:blood / Q000175:diagnosis*; D006801:Humans; D011237:Predictive Value of Tests; D011863:Radioimmunoassay; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000097:blood*
D014408:Biomarkers, Tumor; D014359:Trypsin Inhibitor, Kazal Pancreatic